ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 33.6 | 25.7 | 38.2 |
| Other income | 0.5 | 0.5 | 0.5 |
| Total income | 34.1 | 26.2 | 38.7 |
| Profit before exceptional items & tax | -1.3 | 0.8 | 0.4 |
| Exceptional items | 1.0 | 0.1 | 0.1 |
| Profit before tax | -2.3 | 0.7 | 0.4 |
| Net profit | -2.0 | 0.6 | 0.5 |
| Operating margin | -6.7% | 2.7% | 1.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -12.00% |
|---|
BSE results filing, NSE: TTFL. Figures extracted from the filing.
Trident Texofab Ltd: key numbers
- Share price
- ₹22.57
- Market cap
- ₹33.85 Cr
- Revenue (annual)
- ₹118.0 Cr
- Net profit (annual)
- ₹0.70 Cr
- P/E (TTM)
- -108.0×Sector 48.2×
- Promoter holding
- 32.88%+0.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Trident Texofab Ltd
All →Trident Texofab Q2 FY27 Results: Net Profit ₹0.6 Cr, Down 45.5% YoY
Trident Texofab approved unaudited standalone results for the quarter ended September 2026. Quarterly revenue fell to ₹2,533.77 lakh from ₹3,063.46 lakh a year earlier.
- Key figure
- Net profit ₹0.6 Cr · -45.5% YoY
Trident Texofab Other Announcement
Trident Texofab disclosed that its RTA, KFin Technologies, is shifting its corporate office to Kokapet, Hyderabad, effective 1 December 2026. The registered office stays unchanged and no financial impact is stated.
Trident Texofab Board Meeting Date
Trident Texofab schedules a board meeting on 5 November 2026 to consider unaudited quarterly results. No financial figures are disclosed yet.
Trident Texofab Annual General Meeting
Trident Texofab's EGM on 28 October 2026 sought approval for a statutory auditor to fill a casual vacancy. Only one ordinary resolution was tabled.
Trident Texofab Other Announcement
Trident Texofab Ltd has submitted its quarterly shareholding pattern filing for the period ending September 30, 2026, as per regulatory requirements.
Trident Texofab Management Change
Trident Texofab Limited has appointed M/s. A Bafna & Associates as the new Statutory Auditor for a term of 12 months.